Search clinical trials for: APN201

Total 80 results

Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Solid Neoplasm | Recurrent Solid Neoplasm | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIA Melanoma | Stage IIIB Melanoma and other conditions

United States
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
invIOs GmbH

Recruiting

PBMC-based Leukocyte Immunotherapy (PALINDROM)

Advanced Solid Tumor

Austria
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
Apeiron Biologics

Completed

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)

COVID-19

Denmark, Germany, Austria, Russian Federation, United Kingdom
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Abion Inc
Novotech (Australia) Pty Limited

Recruiting

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Advanced Solid Tumors

Australia, Korea, Republic of
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Regenera Pharma Ltd

Completed

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

Non-arteritic Ischemic Optic Neuropathy | Optic Nerve Injuries

Israel
University of Zurich
ImVision GmbH, Hannover

Completed

Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial (IVN-CAT-001B)

Allergy to Cat Dander

Switzerland
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
Edimer Pharmaceuticals

Active, not recruiting

Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 (ECP-002e)

X-linked Hypohidrotic Ectodermal Dysplasia

United States, United Kingdom, France, Germany, Italy
Edimer Pharmaceuticals

Completed

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (ECP-002)

X-Linked Hypohidrotic Ectodermal Dysplasia

United States, United Kingdom, France, Germany, Italy
Hadassah Medical Organization

Withdrawn

The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements (CVS)

Chronic Vegetative State
Almac Discovery

Terminated

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Ovarian Cancer | Solid Tumors

United Kingdom
Acacia Pharma Ltd

Completed

Pilot Study of APD209 in Cancer Cachexia

Cancer-related Cachexia

United Kingdom
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
Regenera Pharma Ltd

Withdrawn

Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn

Partial Thickness Burn | Second Degree Burn Less Than 5%TBSA

Israel
AP Biosciences Inc.

Not yet recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE)

Esophageal Squamous Cell Carcinoma (ESCC) | Locally Advanced or Metastatic Solid Tumors | Non Small Cell Lung Cancer (NSCLC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
Alebund Pty Ltd

Completed

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

Healthy Subjects

Australia
Pfizer

Completed

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Fungal Infection

United Kingdom
Yonsei University

Not yet recruiting

A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration

Neoplasms
Regenera Pharma Ltd

Completed

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Mild to Moderate Dementia Due to Alzheimer's Disease | With or Without Coexisting Cerebrovascular Disease

Canada
Regenera Pharma Ltd
TransCom Global Ltd. (CRO)

Terminated

Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

Chronic Wound

Israel
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
HK inno.N Corporation

Completed

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301

Parenteral Nutrition

Korea, Republic of
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
CannaXan GmbH

Completed

Clinical Trial on Pharmacokinetic and Tolerability of AP701

Tolerability | Safety | Pharmacokinetic

Germany
Apeiron Biologics

Completed

Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

Cardiovascular Diseases | Kidney Diseases | Pulmonary Diseases | Cancer Diseases

Switzerland
Accure Therapeutics
Simbec Research

Completed

BN201 SAD MAD Study in Healthy Subjects

Optic Neuritis | Optic; Neuritis, With Demyelination

United Kingdom
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Regenera Pharma Ltd
Syneos Health

Completed

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

Healthy Volunteers | Moderate to Severe Alzheimer Patients

Canada
Novus Therapeutics, Inc

Completed

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Healthy Adult Volunteers

United States
Novus Therapeutics, Inc

Completed

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

Acute Otitis Media

United States
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor

Melanoma | Lung Cancer | PD-L1 | PET/CT

China
AnnJi Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Spinal and Bulbar Muscular Atrophy | Kennedy's Disease

United States
Regenera Pharma Ltd

Terminated

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Nonarteritic Anterior Ischemic Optic Neuropathy

United States
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany
Apogenix GmbH

Completed

APG101 in Glioblastoma

Glioblastoma Multiforme

Austria, Germany
CANbridge Life Sciences Ltd.

Completed

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Multiforme

Taiwan
Abion Inc

Completed

To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers

Solid Tumor

Korea, Republic of

Search clinical trials for: APN201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations